Somatostatin content increases following norepinephrine depletion in frontal cortex of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.
The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on somatostatin (SS)-containing neurons were examined by measuring dopamine, norepinephrine (NE), SS, and SS mRNA in striatum and frontal cortex of C57/B16 mice at various times following treatment with MPTP-HCl (96 mg/kg i.p.). MPTP caused a 70% depletion of dopamine in striatum by 1 day and a 40% depletion of NE in frontal cortex within 3 days. SS content was increased in frontal cortex 4 days later, but not in striatum; there were no changes in SS mRNA. Maprotiline, a specific NE-uptake blocker, prevented both the depletion of NE and the increase of SS in frontal cortex due to MPTP administration. These results support the possibility that NE can regulate SS in frontal cortex and are discussed in terms of the decrease of SS seen in parkinsonian patients with dementia.
Clinical Neuroscience Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
K
K
Mitsuo
J P
JP
Schwartz
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D000818:Animals; D004298:Dopamine / Q000378:metabolism; D005625:Frontal Lobe / Q000378:metabolism*; D008297:Male; D008376:Maprotiline / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D009638:Norepinephrine / Q000172:deficiency* / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D013004:Somatostatin / Q000235:genetics / Q000378:metabolism*
D012333:RNA, Messenger; D008376:Maprotiline; D013004:Somatostatin; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine; D009638:Norepinephrine